Category Archives: IPR

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

Indian pharma industry fears tougher US stance on IP

Prices of patented drugs are lower in Canada, United Kingdom and Australia in comparison to the US By Aneesh Phadnis & Reuters| Published: Business Standard | february 1, 2017 Indian pharma industry is fearing a tougher US government stance on intellectual … Continue reading

Posted in Generics, IPR, Uncategorized, US pressure on India | Leave a comment

New Book Highlights IP Trade Law Flexibilities For Public Health

Source: http://www.ip-watch.org A recently published book by a high-impact public health advocate provides new analysis on the use of flexibilities in international trade law relating to intellectual property rights aimed at advancing discussions on solutions to high drug prices worldwide. … Continue reading

Posted in IPR, TRIPS, TRIPS flexibilities, Uncategorized, WTO | Leave a comment

India-EFTA trade deal talks to be held in January

Source: PTI | December 28, 2016 NEW DELHI: With India and the European Free Trade Association (EFTA) members resuming talks for the long-stalled proposed free trade agreement last month, senior officials of the four-nation bloc will visit here in January to … Continue reading

Posted in Data Exclusivity, EFTA-India FTA, IPR, Uncategorized | Leave a comment

How will Trump tackle intellectual property issues?

BY Soh Kar Liang, Today | December 20, 2016  Three weeks after Mr Donald Trump won the United States Presidential Election, he received a request from some of the world’s biggest music producers and Grammy-award winners. The group, comprising members of … Continue reading

Posted in IPR, TPP, Uncategorized | Leave a comment

RCEP trade deal negotiators must reject terms that would harm access to medicines

Source: MSF Access Campaign Geneva/Jakarta, 5 December 2016 – As negotiators from the 16 countries in the Regional Comprehensive Economic Partnership (RCEP) meet in Tangerang, Indonesia, starting today, international medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health … Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, TPP, Uncategorized | 1 Comment

On World AIDS Day, threat to access to medicines looms large

By Shailly Gupta, Jakarta Post| December 2, 2016 Today millions of people living with HIV in South-East Asia are receiving treatment and leading healthy lives thanks to affordable generic antiretroviral (ARVs) medicines. Governments and treatment providers across Asia, such as … Continue reading

Posted in Generics, HIV/Aids, IPR, Regional Comprehensive Economic Partnership, Tuberculosis (TB), Uncategorized | Leave a comment